摘要
<正>近日,沈敬山、蒋华良、朱维良、许叶春和阿吉艾克拜尔·艾萨研究团队在期刊Journal of Medicinal Chemistry(美国化学会)上发表了题为Pharmacokinetics-Driven Optimization of 4(3H)-Pyrimidinones as Phosphodiesteras Type 5 Inhibitors Leading to TPN171, a Clinical Candidate for the Treatment of Pulmonary Arterial Hypertension的封面文章。文章报道了研究人员从肺动脉高压(PAH)治疗的临床需求出发,
- 单位